We want to stop lives being devastated by pulmonary fibrosis. Our five year strategy, launched in 2024 sets out our ambitious plans to achieve this.
We have achieved so much together in the last 11 years but today we are needed more than ever.
APF works with pharmaceutical companies to advance research and improve access to treatments for PF, always in line with the ABPI Code of Practice and our own policies. As an AMRC member, our contracts explicitly commit us to upholding these standards. Alongside commercial income received for services, we occasionally receive grants or donations from industry; for example, in support of PF Awareness Month. In such cases, support is clearly acknowledged on relevant materials, reported in our annual accounts, and published by ABPI. Importantly, APF remains fully independent; pharmaceutical partners have no decision-making influence over our work.
We'd like to thank the following companies for their support during our financial year 2024/2025:
Boehringer Ingelheim
Trevi
Endeavor
Vicore
Bristol Myers Squibb